Breast cancer and protein biomarkers.
暂无分享,去创建一个
[1] C. Richard,et al. The Potential of BORIS Detected in the Leukocytes of Breast Cancer Patients as an Early Marker of Tumorigenesis , 2006, Clinical Cancer Research.
[2] Daohai Zhang,et al. Over-expression of ERp29 attenuates doxorubicin-induced cell apoptosis through up-regulation of Hsp27 in breast cancer cells. , 2010, Experimental cell research.
[3] L. Gam,et al. The PCA and LDA Analysis on the Differential Expression of Proteins in Breast Cancer , 2011, Disease markers.
[4] J. Birch. Genes and cancer , 1999, Archives of disease in childhood.
[5] P. Drew,et al. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID? , 2012, Journal of proteomics.
[6] N. Peat,et al. Structure and biology of a carcinoma-associated mucin, MUC1. , 1991, The American review of respiratory disease.
[7] S. Barnhill,et al. CA 125: The past and the Future , 1998, The International journal of biological markers.
[8] R. Nahta,et al. Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. , 2009, Current pharmacogenomics and personalized medicine.
[9] N. Anderson,et al. A List of Candidate Cancer Biomarkers for Targeted Proteomics , 2006, Biomarker insights.
[10] Enrique Parás Chavero. The past and the future , 1965 .
[11] B. Kramer,et al. Trends in biomarker research for cancer detection. , 2001, The Lancet. Oncology.
[12] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] T. Eberlein,et al. Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T‐cell activation , 1999, International journal of cancer.
[14] Kit S. Lam,et al. A Serum Glycomics Approach to Breast Cancer Biomarkers*S , 2007, Molecular & Cellular Proteomics.
[15] P. Kantoff,et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[17] A. Melnick,et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models , 2009, Proceedings of the National Academy of Sciences.
[18] M. Duffy,et al. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? , 2001, Clinical chemistry.
[19] B. Hulka,et al. Breast cancer: hormones and other risk factors. , 2001, Maturitas.
[20] H. Körner,et al. Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis , 2006, The Journal of pathology.
[21] K. Baggerly,et al. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2‐positive breast cancer using an LC‐MALDI‐TOF/MS procedure , 2010, Proteomics.
[22] Bin Wen,et al. Comparative Proteome Analysis of Breast Cancer and Adjacent Normal Breast Tissues in Human , 2006, Genom. Proteom. Bioinform..
[23] Jing Wang,et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes , 2008, Nature Immunology.
[24] E. Petricoin,et al. Proteomics of human breast ductal carcinoma in situ. , 2002, Cancer research.
[25] D. Noh,et al. Proteomic approach reveals FKBP4 and S100A9 as potential prediction markers of therapeutic response to neoadjuvant chemotherapy in patients with breast cancer. , 2012, Journal of proteome research.
[26] Mukesh Verma,et al. Proteomics for Cancer Biomarker Discovery , 2002 .
[27] P. Drew,et al. Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer. , 2012, Journal of proteomics.
[28] Stephen Russell,et al. Proteomics of breast carcinoma. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[29] L. Chow,et al. Changes in protein expression after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance , 2010, Expert opinion on investigational drugs.
[30] R. Bast,et al. Status of tumor markers in ovarian cancer screening. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[32] Hai Hu,et al. Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization. , 2004, Cancer genetics and cytogenetics.
[33] M. Magee,et al. Increased mortality associated with elevated carcinoembryonic antigen in insurance applicants. , 2007, Journal of insurance medicine.
[34] C. Fabian. Surrogates are just surrogates, but helpful just the same , 2007, Breast Cancer Research.
[35] V. Levenson,et al. Biomarkers for early detection of breast cancer: what, when, and where? , 2007, Biochimica et biophysica acta.
[36] R. Caprioli,et al. Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation , 2010, Clinical Cancer Research.
[37] G. Clark. Interpreting and integrating risk factors for patients with primary breast cancer. , 2001, Journal of the National Cancer Institute. Monographs.
[38] Yang Zhang,et al. Expression of cell-cycle regulatory proteins BUBR1, MAD2, Aurora A, cyclin A and cyclin E in invasive ductal breast carcinomas. , 2011, Histology and histopathology.
[39] M. Mandal,et al. Growth Factor Receptors and Apoptosis Regulators: Signaling Pathways, Prognosis, Chemosensitivity and Treatment Outcomes of Breast Cancer , 2009, Breast cancer : basic and clinical research.
[40] K. Pritzker,et al. Cancer biomarkers: easier said than done. , 2002, Clinical chemistry.
[41] L. Gam,et al. The Differential Expression of Aqueous Soluble Proteins in Breast Normal and Cancerous Tissues in Relation to Ethnicity of the Patients; Chinese, Malay and Indian , 2010, Disease markers.
[42] John M S Bartlett,et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] J. Robertson,et al. MUC-1 mucin assays for monitoring therapy in metastatic breast cancer , 1998 .
[44] F. Révillion,et al. Proteomic analysis reveals that 14-3-3σ is down-regulated in human breast cancer cells , 2001 .